Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
Cutera Inc (CUTR) is a global leader in medical aesthetics, pioneering advanced laser systems for skin treatments and body contouring. This page serves as the definitive source for official company announcements, financial disclosures, and technology developments.
Access real-time updates on earnings reports, FDA clearances, product launches, and strategic partnerships. Investors and practitioners alike rely on this centralized hub for tracking innovations in energy-based aesthetic devices and corporate milestones.
Our curated news feed includes clinical study results, regulatory updates, and market expansion announcements. Stay informed about CUTR's advancements in ND:YAG technology and international service network developments through verified primary sources.
Bookmark this page for streamlined access to CUTR's evolving position in the $6B medical aesthetics sector. Check regularly for critical updates affecting treatment protocols, device safety profiles, and corporate financial health.
Cutera (Nasdaq: CUTR) has appointed Jeryl 'Jeri' Hilleman to its Board of Directors, effective July 12, 2024. Hilleman brings over 30 years of experience in the healthcare industry, with a strong background in financial leadership, strategic planning, and corporate governance. She has served as CFO for multiple public healthcare companies, including Intersect ENT, Ocera Therapeutics, and Amyris. CEO Taylor Harris highlighted her expertise as critical for Cutera's growth and innovation, particularly with products like AviClear. Hilleman has also held significant governance roles, such as Chair of the Board at Omada Health and Audit Committee Chair at NovoCure, Minerva Neurosciences, and others.
Cutera announced an investor webinar to present AviClear, the first FDA-cleared energy device for treating inflammatory acne, on June 20, 2024, at 11 a.m. PDT. The session will cover clinical data, market potential, future studies, and user experiences. Key speakers include CEO Taylor Harris, CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, and dermatologists Dr. David J. Goldberg and Dr. Sonia Batra. The event will conclude with a live Q&A session for analysts and investors. Participants can join via the provided link or phone numbers. A replay will be available on Cutera’s website the next day.
Cutera, a leader in aesthetic and dermatology solutions, announced the granting of 44,500 non-qualified inducement stock options to six employees. Approved by the Compensation Committee of Cutera's Board of Directors, these options have an exercise price of $2.23, matching the closing price of Cutera's stock on the grant date, May 13, 2024.
The vesting schedule is as follows: 25% of the 29,500 stock options granted to five employees will vest annually, with an additional 1/48 vesting monthly, contingent on continued employment. For the remaining 15,000 stock options granted to one employee, 33% will vest annually with 1/36 vesting monthly, also subject to continued employment. These awards are part of Cutera's 2023 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Cutera, Inc. (Nasdaq: CUTR) reported Q1 2024 financial results with revenue of $38.8 million, a 29% decrease from the previous year. The company highlighted a strong sequential increase in AviClear revenue and the successful launch of xeo+. Gross profit was $12.4 million, operating expenses were $31.9 million, and cash equivalents were $105.4 million. Cutera reiterated its 2024 revenue guidance of $160-170 million.
FAQ
What is the current stock price of Cutera (CUTR)?
What is the market cap of Cutera (CUTR)?
